首页 > 市场调查报告书 > 製药

循环系统

市场调查报告书

商品编码

1122334

钙通道阻滞剂市场：按药物类别、适应症（高血压、胸痛、心律失常等）、按分销渠道、按地区 - 规模、份额、前景、机会分析，2022-2030

Calcium Channel Blocker Drugs Market, by Drug Class, by Disease Indication (Hypertension, Chest Pain, Arrhythmias, and Others ), by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: 2022年08月16日 | 出版商:

Coherent Market Insights | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

简介目录

钙拮抗剂是用于治疗与心绞痛相关的高血压、心律失常和胸痛的药物，通过阻断一些进入心臟和动脉的钙而有效。钙通道阻滞剂有许多不同的类型，从短效溶解片剂到缓释胶囊。剂量取决于患者的一般情况和病史。

此外，慢性肾病是一种肾功能在数年内逐渐下降的疾病。随着肾功能衰竭的进展和器官功能的严重受损，危险水平的废物和水会在体内迅速积聚。治疗旨在阻止或减缓疾病的进展，而根本原因钙通道阻滞剂通常用于治疗慢性肾病或其根本原因。

市场动态

预计心血管疾病、肥胖和不健康生活方式的流行将在预测期内推动市场增长。

例如，根据世界卫生组织 2022 年的数据，2019 年估计有 1790 万人死于心血管疾病，其中 85% 的死亡发生在全球心脏病发作和中风。

预计钙通道阻滞剂的不断推出和批准将标誌着预测期内市场的显着增长。

例如，2022 年 6 月，製药公司 CMP Pharma 宣布了 1mg 的长效钙通道阻滞剂氨氯地平苯磺酸盐口服液，用于治疗 6 岁及以下患者的高血压。/ML，其 Noricva（氨氯地平）口服溶液获得美国食品和药物管理局的批准。

本研究的主要特点

本报告对以 2021 年为基准年的预测期（2022-2030 年）内的全球钙通道阻滞剂市场、市场规模（百万美元）和復合年增长率 (CAGR%) 进行了深入分析。增加。
解释不同细分市场的潜在收入机会，并描述该市场具有吸引力的投资建议矩阵。
它还提供有关市场驱动因素、限制因素、机会、新产品发布和批准、市场趋势、区域前景以及主要参与者采用的竞争策略的重要见解。
基于公司亮点、产品组合、关键亮点、业绩和战略等参数的全球钙拮抗剂市场主要参与者的概况。
本研究涵盖的主要公司包括：Bausch Health, Mylan N.V., Teva Pharmaceutical Industries Ltd, Lupin, Arbor Pharmaceuticals, GlaxoSmithKline Plc, Biopharma, Sofgen Pharmaceuticals, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Novartis AG, Zydus Cadila and Pfizer Inc,
此报告中的见解将使营销人员和企业高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。这似乎是一回事。
全球钙拮抗剂市场报告迎合了该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和财务分析师。
利益相关者可以通过用于分析全球钙通道阻滞剂市场的各种策略矩阵来促进他们的决策。

内容

第 1 章目的和先决条件

调查目的
先决条件
缩写说明

第二章市场展望

举报内容
- 市场定义和范围
执行摘要
- 市场细分：按药物类别
- 市场细分：按指示
- 市场细分：按分销渠道
- 按地区划分的市场细分
连贯的机会图 (COM)

第 3 章市场动态、监管和趋势分析

驱动程序
限制因素
商机
影响分析
主要发展战略
併购场景
市场趋势
品牌分析
监管场景
PEST 分析
定价分析

第 4 章全球钙通道阻滞剂市场 - 冠状病毒 (COVID-19) 大流行的影响

COVID-19 的流行病学特征
对製造业的影响
对製造业的影响

第 5 章全球钙通道阻滞剂市场，按药物类别，2017-2030 年

苯佐西平
二氢□啶
苯烷基胺

第 6 章全球钙通道市场：按疾病适应症，2017-2030

高血压
胸痛
心律失常
其他（血管疾病、冠状动脉疾病等）

第 7 章。全球钙通道阻滞剂市场，按分销渠道：2017-2030 年

医院药房
零售药房
在线药店

第 8 章全球钙通道阻滞剂市场：按地区分列，2017-2030 年

北美
美国
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
其他拉丁美洲地区
欧洲
德国
英国
法国
意大利
西班牙
俄罗斯
其他欧洲地区
亚太地区
中国
印度
日本
澳大利亚
韩国
东盟
其他亚太地区
中东
海合会
以色列
其他中东
非洲
南非
中非
北非

第 9 章竞争格局

Competitive Snapshot
- Bausch Health
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd
- Lupin
- Arbor Pharmaceuticals
- GlaxoSmithKline Plc
- Biopharma
- Sofgen Pharmaceuticals
- Glenmark Pharmaceuticals Inc
- Amneal Pharmaceuticals
- Sun Pharmaceutical Industries Ltd,
- Novartis AG
- Zydus Cadila
- Pfizer Inc,

第 10 章

参考资料
调查方法

简介目录

Product Code: CMI5153

Calcium channel blockers are class of medicines used for the treatment of hypertension, irregular heartbeats called arrhythmias and chest pain related to angina they work by blocking some of the calcium that enters the heart and arteries. Calcium channel blocker drugs are available in many forms which ranging from short-acting dissolving tablets to extended-release capsules. The dosage will depend on overall health and medical history of patients.

Moreover, chronic kidney disease is the progressive loss of kidney function over a period of several years. As kidney failure advances to further stages, and the organ's function is severely impaired, dangerous levels of waste and fluid can rapidly build up in the body. Treatment is aimed at stopping or slowing down the progression of the disease - this is usually done by controlling its underlying cause calcium channel blockers are drug used in the treatment of chronic kidney disease or its underlying cause.

Market Dynamics

Increasing prevalence of cardiovascular disease, obesity, unhealthy life style is expected to drive the market growth during the forecast period.

For instance, according to the World Health Organization 2022, an estimated 17.9 million people are died from cardiovascular disease in 2019 form which 85% death are occur due to heart attack and stroke worldwide.

Increasing lunches and approval of calcium channel blocker drug is expected to witness significant growth of the market over the forecast period

For instance, in June 2022, CMP Pharma, Inc., a pharmaceutical company receive the U.S. Food and Drug Administration approval for its Norliqva (amlodipine) oral solution, 1 mg/mL, an oral liquid solution of the besylate salt of amlodipine, a long-acting calcium channel blocker for the treatment of hypertension in patients 6 years of age and older.

Key features of the study:

This report provides an in-depth analysis of the global calcium channel blocker drugs market, market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global calcium channel blocker drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Bausch Health, Mylan N.V., Teva Pharmaceutical Industries Ltd, Lupin, Arbor Pharmaceuticals, GlaxoSmithKline Plc, Biopharma, Sofgen Pharmaceuticals, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Novartis AG, Zydus Cadila and Pfizer Inc,
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global calcium channel blocker drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global calcium channel blocker drugs market

Detailed Segmentation:

Global Calcium Channel Blocker Drugs Market, By Drug Class:
- Benzothizepine
- Dihydropyridine
- Phenylalkylamine
Global Calcium channel blocker drugs market, By Disease Indication:
- Hypertension
- Chest Pain
- Arrhythmias
- Others (Blood vessel conditions, Coronary Artery Disease etc.)
Global Calcium Channel Blocker Drugs Market, By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Global Calcium Channel Blocker Drugs Market, By Region:
- North America
  - By Country
- U.S.
- Canada
- Latin America
  - By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country
- U.K.
- Germany
- France
- Spain
- Italy
- Russia
- Rest Of Europe
- Asia Pacific
  - By Country
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
  - By Country
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Country/Region
- South Africa
- Central Africa
- North Africa
Company Profiles
- Bausch Health*
  - Company Overview
  - Disease Indication Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd
- Lupin
- Arbor Pharmaceuticals
- GlaxoSmithKline Plc
- Biopharma
- Sofgen Pharmaceuticals
- Glenmark Pharmaceuticals Inc
- Amneal Pharmaceuticals
- Sun Pharmaceutical Industries Ltd,
- Novartis AG
- Zydus Cadila
- Pfizer Inc,

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Disease Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Drivers
Restraints
Opportunities
Impact Analysis
Key Development Strategies
Mergers And Acquisition Scenario
Market Trends
Brand Analysis
Regulatory Scenario
PEST Analysis
Pricing Analysis

4. Global Calcium Channel Blocker Drugs Market - Impact of Coronavirus (Covid-19) Pandemic

COVID-19 Epidemiology
Impact on Manufacturing
Impact on Manufacturing

5. Global Calcium Channel Blocker Drugs Market, By Drug Class, 2017 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017-2030
- Segment Trends
Benzothizepine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Dihydropyridine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Phenylalkylamine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)

6. Global Calcium Channel Blocker Drugs Market, By Disease Indication, 2017 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017-2030
- Segment Trends
Hypertension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Chest Pain
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Arrhythmias
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Others (Blood vessel conditions, Coronary Artery Disease etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)

7. Global Calcium Channel Blocker Drugs Market, By Distribution Channel, 2017 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017-2030
- Segment Trends
Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)

8. Global Calcium Channel Blocker Drugs Market, By Region, 2017 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
North America
- Market Size and Forecast, By Drug Class, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
U.S.
Canada
Latin America
- Market Size and Forecast, By Drug Class, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Market Size and Forecast, By Drug Class, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
- Market Size and Forecast, By Drug Class, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
- Market Size and Forecast, By Drug Class, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
- Market Size and Forecast, By Drug Class, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Region/Country, 2017 - 2030, (US$ Mn)
South Africa
Central Africa
North Africa